Back to Search
Start Over
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
- Source :
- Therapeutics and Clinical Risk Management
- Publication Year :
- 2016
-
Abstract
- Seda Tural Onur,1 Sinem Nedime Sokucu,1 Levent Dalar,2 Sinem Iliaz,1 Kaan Kara,1 Songül Buyukkale,3 Sedat Altin1 1Department of Chest Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, 2Department of Pulmonary Medicine, Faculty of Medicine, Istanbul Bilim University, 3Department of Thoracic Surgery, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey Background: Malignant mesothelioma (MM) is an aggressive asbestos-related pleural tumor. The incidence is increasing with intensive use of asbestos in developing countries. We need an easily accessible, inexpensive, and reliable method for determining the low survival time prognosis of this tumor. The aim of our study was to investigate the viability of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) as prognostic indicators in MM. Patients and methods: Thirty-six patients with MM, whose histopathologic diagnosis and follow-up were performed by our clinic and whose complete archive data were accessible, were included in this retrospective study. The patients’ histopathologic disease types and stages, complete blood count parameters at diagnosis, and survival were recorded. Results: Eighteen of the patients with MM were male and the remaining 18 of them were female; the average follow-up period was 24.83±3.61months. The PLR levels of the patients were statistically significant (P
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Pathology
Therapeutics and Clinical Risk Management
Lymphocyte
Pleural Tumor
medicine.disease_cause
survival
Asbestos
03 medical and health sciences
0302 clinical medicine
Internal medicine
Medicine
Pharmacology (medical)
Platelet
Mesothelioma
General Pharmacology, Toxicology and Pharmaceutics
Platelet lymphocyte ratio
Original Research
Chemical Health and Safety
business.industry
Incidence (epidemiology)
General Medicine
medicine.disease
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
malignant mesothelioma
neutrophil/lymphocyte ratio
platelet/lymphocyte ratio
business
Safety Research
Subjects
Details
- ISSN :
- 11766336
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Therapeutics and clinical risk management
- Accession number :
- edsair.doi.dedup.....96b3c525de73d32ed3cd4410ebe9ac37